Oxitec achieved a major regulatory milestone in August 2007, with United States and Malaysia granting regulatory approval for contained trials of Oxitec’s RIDL Aedes aegypti mosquito strains to leading research institutions in these two countries. Oxitec’s head of public health S.S. Vasan said: “This will pave the way for independent evaluation of our promising RIDL technology to control Aedes aegypti – the primary mosquito vector of dengue, chikungunya and yellow fever viruses. Our technology has already been cage-tested at the Institut Pasteur in France, and India’s Review Committee on GM is examining a proposal to conduct further evaluation under containment.” It is worth noting that 55% of the world’s population in 124 countries are at risk from dengue, according to the International Vaccine Institute based in Seoul.
Cornell and Colorado State Universities have been granted permits by the US Department of Agriculture Biotechnology Regulatory Services effective 30 July and 23 August 2007 respectively. The WHO Collaborating Centre for Vectors at the Institute for Medical Research (IMR / Ministry of Health / Government of Malaysia) has been granted regulatory clearance by the national Genetic Modification Advisory Committee (GMAC / Ministry of Natural Resources & Environment / Government of Malaysia) effective 28 August 2007.